12月4日,科伦博泰(HK06990)与Crescent Biopharma, Inc. (一家纳斯达克上市公司,以下简称Crescent)共同宣布,双方已建立战略合作伙伴关系。科伦博泰方面将ADC药物(抗体偶联药物)SKB105在中国以外权利授权Crescent,并预计将获得最高超13亿美元的授权收入。而后者将核心管线PD-1/VEGF双抗CR-001(PD-1意为程序性细胞死亡-1,VEGF...
Source Link12月4日,科伦博泰(HK06990)与Crescent Biopharma, Inc. (一家纳斯达克上市公司,以下简称Crescent)共同宣布,双方已建立战略合作伙伴关系。科伦博泰方面将ADC药物(抗体偶联药物)SKB105在中国以外权利授权Crescent,并预计将获得最高超13亿美元的授权收入。而后者将核心管线PD-1/VEGF双抗CR-001(PD-1意为程序性细胞死亡-1,VEGF...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.